Saifuse Co., Ltd.

Since its founding in 2010, Saifuse has produced three‑dimensional tissues and organs using only cells, pursuing a mission of social contribution in medical fields such as regenerative medicine and drug discovery.

After working as a researcher in genetics and regenerative medicine at Kyushu University, he participated in a JST project (commercialization of bone‑cartilage regeneration) at Kyushu University Hospital. He joined Saifuse as a founding member in 2010 and has overseen national projects such as AMED and NEDO, as well as Saifuse‑related research and development projects, driving development to commercialization in regenerative medicine through industry‑academia‑government collaboration.

Saifuse Co., Ltd. was established in August 2010.

Establishment of Saifuse Co., Ltd.

In September 2010, Saifuse Co., Ltd. was selected for the NEDO 'Bridge Promotion Technology Development' program in collaboration with Kyushu University.

Jointly selected with Kyushu University for NEDO's "Bridge‑Promotion Technology Development".

After engineering experience at NEC System Construction Co., Ltd. (now NEC Nets SI Co., Ltd.) and others, he joined the new audit firm (now PwC Japan Limited Liability Audit Firm) in 2012, engaging broadly in accounting audits, internal control audits, and system audits for listed and unlisted companies.

In December 2012, the company began selling the Bio 3D printer 'Regenova®' (product name: Regenova®).

Commenced sales of the bio‑3D printer "Regenova®" (product name: Regenova®).

In April 2013, a headquarters lab was established at the University of Tokyo Entrepreneurial Plaza.

Established a headquarters lab at the University of Tokyo Entrepreneurial Plaza.

In April 2014, the company was selected for AMED's commissioned project 'Development of functional tissue manufacturing technology by 3D printing / Research and development of functional 3D tissue creation technology using cells.'

Selected for AMED's commissioned project "Development of functional tissue manufacturing technology by 3D printing / Research and development of functional 3D tissue creation technology using cells".

In July 2017, the company joined AMED's commissioned project 'Innovative Medical Seed Utilization Research Project / Clinical development of innovative peripheral nerve regeneration using a 3D-printed neural conduit (Bio 3D Conduit)' (representative: Kyoto University).

Joined AMED's commissioned project "Innovative Medical Seed Utilization Research Project / Clinical development of an innovative peripheral nerve regeneration method using a 3D‑printed neural conduit (Bio 3D Conduit)" (representative: Kyoto University).

In August 2017, the company received the Japan Science and Technology Agency Chairman's Award at the University-Founded Venture Awards and the Japan Academy President's Award for Industry-Academia-Government Collaboration.

Received the Japan Science and Technology Agency Chairman's Award at the University-Founded Venture Award, and the Japan Academy President's Award at the Industry-Academia-Government Collaboration Award.

In February 2018, the company was selected for the 'Next-Generation Innovation Creation Project 2020 Grant' conducted by the Tokyo Metropolitan Small and Medium Enterprise Promotion Corporation.

Selected for the "Next-Generation Innovation Creation Project 2020 Grant" conducted by the Tokyo Metropolitan Small and Medium Enterprise Promotion Corporation.

In August 2018, the company was selected for NEDO's 'Research and Development Venture Support Project / Business Development Support for Intercompany Collaborative Startups.'

Selected for the NEDO "Research and Development Venture Support Project / Business Development Support for Intercompany Collaboration Startups".

In January 2019, the company began selling the Bio 3D printer 'S-PIKE®' (product name: Spike®).

Launch of the Bio 3D printer "S-PIKE®" (product name: Spike®).

In February 2019, the company received the Small and Medium Enterprise Agency Chairman's Award at the JAPAN VENTURE AWARDS.

Received the Small and Medium Enterprise Agency Chairman's Award at the JAPAN VENTURE AWARDS.

In May 2019, the company was certified as a 'TOKYO Work Style Reform Declaration Company' by the Tokyo Metropolitan Government.

Certified as a "TOKYO Work Style Reform Declaration Company" by the Tokyo Metropolitan Government.

In June 2019, the company was selected as a J-Startup by the Ministry of Economy, Trade and Industry.

Selected as a J-Startup company by the Ministry of Economy, Trade and Industry's startup support program.

In November 2019, the company joined AMED's commissioned project 'Clinical research of small-diameter scaffold-free cell artificial blood vessels fabricated using a Bio 3D printer' (representative: Saga University).

Participated in AMED's commissioned project "Clinical Research on Small-Caliber Scaffold-Free Cell Artificial Blood Vessels Fabricated Using a Bio 3D Printer."

In May 2020, the company joined AMED's commissioned project 'Safety and efficacy evaluation of 3D neural conduit transplantation for peripheral nerve injury, physician-led clinical trial' (representative: Kyoto University).

Participated in AMED's commissioned project "Physician-initiated Clinical Trial Investigating the Safety and Efficacy of 3D Neural Conduit Transplantation for Peripheral Nerve Injury."

In November 2020, the company started a physician-led clinical trial of a 3D neural conduit for peripheral nerve injury using a Bio 3D printer at Kyoto University Hospital.

Initiated a physician-led clinical trial of 3D neural conduits for peripheral nerve injury using a Bio 3D printer at Kyoto University Hospital.

In April 2022, the Tokyo office relocated to Mita, Minato-ku, Tokyo.

Moved the Tokyo office to Mita, Minato-ku, Tokyo.

In September 2022, the Fukuoka office moved to Tenjin Business Center.

Moved the Fukuoka office to Tenjin Business Center.

In December 2022, the company went public on the Tokyo Stock Exchange Growth Market.

Newly listed on the Tokyo Stock Exchange Growth Market.

In 2023, established Mizuuchi Certified Public Accountant & Tax Accountant Office, which has extensive support experience in accounting areas such as bookkeeping and internal controls for small to large enterprises, as well as IT areas such as information security.

In April 2023, completed a physician‑led clinical trial of a 3D neural conduit for peripheral nerve injury using a bio‑3D printer at Kyoto University Hospital.

Completed the physician-led clinical trial of 3D neural conduits for peripheral nerve injury using a Bio 3D printer at Kyoto University Hospital.

In September 2023, joined the AMED commissioned project "Development of an innovative periodontal regenerative therapy using 3D‑printed transplant tissues" (representative: Hiroshima University).

Participated in AMED's commissioned project "Development of Innovative Periodontal Regeneration Therapy Using 3D Transplant Tissue Fabricated with a Bio 3D Printer."

In October 2023, began sales of the new drug‑development support product "Human 3D Mini‑Liver".

Launch of the new drug discovery support product "Human 3D Mini Liver."

In April 2024, received the "Minister of Economy, Trade and Industry Award" at the 2024 (Reiwa 6) Intellectual Property Contribution Award presented by the Ministry of Economy, Trade and Industry and the Japan Patent Office.

Received the Minister of Economy, Trade and Industry Award at the 2024 Intellectual Property Contribution Award.

In May 2024, joined the AMED bridge‑research program "Bone‑cartilage regenerative therapy for idiopathic osteonecrosis of the knee using bio‑3D printer technology" (representative: Keio University).

Participated in AMED Bridge Research Program "Bone and Cartilage Regeneration Therapy for Idiopathic Osteonecrosis of the Knee Using Bio 3D Printer Technology."

In November 2024, "Human 3D Mini‑Liver" received the Encouragement Award at the Tokyo Venture Technology Award presented by the Tokyo Metropolitan Government.

Received the Encouragement Award for "Human 3D Mini Liver" at the Tokyo Venture Technology Award presented by the Tokyo Metropolitan Government.

In April 2025, conducted information dissemination, technology promotion, and new medical education through participation in the Japan International Expo (Osaka/Kansai Expo).

Promoted information dissemination, technology dissemination, and new medical enlightenment through participation in the 2025 Japan International Exposition (Osaka/Kansai Expo).

In October 2025, joined the AMED commissioned project "Research and development of a physician‑led clinical trial of 3D neural conduit transplantation using allogeneic umbilical‑cord‑derived mesenchymal stem cells for peripheral nerve injury" (representative: Kyoto University).

Participated in AMED's commissioned project on research and development of physician-led clinical trials using allogeneic umbilical cord-derived mesenchymal stem cells for 3D nerve conduit transplantation therapy for peripheral nerve injury.

In December 2025, listed on the Fukuoka Stock Exchange Q‑Board market.

In December 2025, entered into a business‑capital partnership with Kurea Co., Ltd. to advance the industrialization and societal implementation of regenerative medicine.

Listed on the Q-Board market of the Fukuoka Stock Exchange.

Entered into a business capital partnership with Kurea Co., Ltd. toward the industrialization and societal implementation of regenerative medicine.